Inventor · disambiguated record
Julianne Smith
Also filed as: SMITH JULIANNE · SMITH JULIANNE N P
24 granted patents·26 pending applications·137 citations·filing 2004–2024
95Inventor score
Top patents by PatentIndex Score
50 records- 0196US11077144B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2020·Granted Aug 3, 2021·7 cites·17 claims
- 0295US10286007B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2017·Granted May 14, 2019·12 cites·18 claims
- 0395US7842489B2Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofCELLECTIS·Filed 2010·Granted Nov 30, 2010·63 cites·7 claims
- 0494US11274316B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2021·Granted Mar 15, 2022·2 cites·5 claims
- 0594US10874693B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2014·Granted Dec 29, 2020·7 cites·11 claims
- 0691US10363270B2Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapyCELLECTIS·Filed 2017·Granted Jul 30, 2019·6 cites·7 claims
- 0790US10426795B2Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cellsCELLECTIS·Filed 2013·Granted Oct 1, 2019·8 cites·17 claims
- 0889US2024309397A1Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapyCELLECTIS·Filed 2023·Application pending·0 cites
- 0988US10378026B2RNA based method to obtain stably integrated retroviral vectorsCELLECTIS·Filed 2014·Granted Aug 13, 2019·6 cites·11 claims
- 1087US11304975B2Methods for engineering allogeneic and highly active t cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 19, 2022·4 cites·6 claims
- 1187US10342829B2Multi-chain chimeric antigen receptor and uses thereofCELLECTIS·Filed 2013·Granted Jul 9, 2019·6 cites·6 claims
- 1286US11891614B2Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapyCELLECTIS·Filed 2020·Granted Feb 6, 2024·1 cites·16 claims
- 1386US10517896B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2019·Granted Dec 31, 2019·2 cites·19 claims
- 1485US11014989B2Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapyCELLECTIS·Filed 2016·Granted May 25, 2021·2 cites·24 claims
- 1584US12458606B2Polymer nanoparticle compositions for in vivo expression of polypeptidesBATTELLE MEMORIAL INSTITUTE·Filed 2024·Granted Nov 4, 2025·0 cites·8 claims
- 1684US11944643B2Universal anti-CD22 chimeric antigen receptor engineered immune cellsCELLECTIS SA·Filed 2018·Granted Apr 2, 2024·2 cites·12 claims
- 1782US2022177914A1Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cellsCELLECTIS·Filed 2022·Application pending·0 cites
- 1881US12133867B2Universal anti-CD22 chimeric antigen receptor engineered immune cellsCELLECTIS SA·Filed 2023·Granted Nov 5, 2024·0 cites·24 claims
- 1979US11414674B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2019·Granted Aug 16, 2022·0 cites·10 claims
- 2079US10259876B2Chimeric antigen receptors targeting epidermal growth factor receptor variant IIIPFIZER·Filed 2017·Granted Apr 16, 2019·3 cites·21 claims
- 2179US9273296B2Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereofSMITH JULIANNE·Filed 2008·Granted Mar 1, 2016·5 cites·31 claims
- 2279US2025026808A1Universal anti-cd22 chimeric antigen receptor engineered immune cellsCELLECTIS SA·Filed 2024·Application pending·0 cites
- 2377US11311575B2Methods for engineering highly active T cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 26, 2022·1 cites·15 claims
- 2477US11007224B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2020·Granted May 18, 2021·0 cites·10 claims
- 2573US2024269178A1Cd19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2023·Application pending·0 cites
- 2672US11603539B2Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapyCELLECTIS·Filed 2013·Granted Mar 14, 2023·0 cites·9 claims
- 2770US2023201260A1Methods for engineering allogeneic and highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 2870US2018360883A1Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapyCELLECTIS·Filed 2018·Application pending·0 cites
- 2970US2022227874A1Chimeric antigen receptors targeting epidermal growth factor receptor variant iiiPFIZER·Filed 2022·Application pending·0 cites
- 3067US2023050345A1Methods for engineering allogeneic and highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 3163US11267892B2Chimeric antigen receptors targeting epidermal growth factor receptor variant IIIPFIZER·Filed 2019·Granted Mar 8, 2022·0 cites·48 claims
- 3262US2014121115A1Custom-made meganuclease and use thereofARNOULD SYLVAIN·Filed 2012·Application pending·0 cites
- 3361US2016273003A1Use of meganucelases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofCELLECTIS SA·Filed 2016·Application pending·0 cites
- 3460US2023056268A1Methods for engineering highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 3558US2011151539A1Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofARNOULD SYLVAIN·Filed 2011·Application pending·0 cites
- 3657US2012159659A1Custom-made meganuclease and use thereofARNOULD SYLVAIN·Filed 2010·Application pending·0 cites
- 3757US2006153826A1Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofARNOULD SYLVAIN·Filed 2004·Application pending·0 cites
- 3857US2021000869A9Cd19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2019·Application pending·0 cites
- 3957US2024074981A1Non-viral delivery of small molecule therapeuticsBATTELLE MEMORIAL INSTITUTE·Filed 2023·Application pending·0 cites
- 4057US2006206949A1Custom-made meganuclease and use thereofARNOULD SYLVAIN·Filed 2004·Application pending·0 cites
- 4155US2010146651A1Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereofCELLECTIS·Filed 2007·Application pending·0 cites
- 4251US2009222937A1Meganuclease variants cleaving a dna target sequence from a xeroderma pigmentosum gene and uses thereofCELLECTIS·Filed 2007·Application pending·0 cites
- 4350US2013061341A1Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereofARNOULD SYLVAIN·Filed 2012·Application pending·0 cites
- 4450US2015017136A1Methods for engineering allogeneic and highly active t cell for immunotherapyCELLECTIS·Filed 2013·Application pending·0 cites
- 4550US2015273055A1Methods and compositions for expanding hematopoietic stem and progenitor cellsUNIV ROCHESTER·Filed 2013·Application pending·0 cites
- 4644US10752670B2Anti-GD3 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2016·Granted Aug 25, 2020·0 cites·12 claims
- 4744US2016138047A1Improved polynucleotide sequences encoding tale repeatsCELLECTIS·Filed 2014·Application pending·0 cites
- 4844US2013059387A1Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereofSMITH JULIANNE·Filed 2012·Application pending·0 cites
- 4939US2012171191A1Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereofCHOULIKA ANDRE·Filed 2010·Application pending·0 cites
- 5039US2015315557A1Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereofCELLECTIS·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Julianne Smith files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →